Form 4: Exact Sciences Executive Brian Baranick Reports Stock Sale

Brian Baranick, EVP, GM., Precision Oncology at Exact Sciences Corp, reported the sale of 924 shares of common stock at a price of $79.43 per share on April 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On April 2, 2024, Brian Baranick, an executive at Exact Sciences Corp, sold 924 shares of common stock at $79.43 per share.
• The sale was executed under a Rule 10b5-1 trading plan established on May 24, 2023.
• Following the transaction, Baranick directly owns 13,171 shares of common stock.
• Baranick also indirectly owns 454 shares in a 401(k) plan.
• In addition to the directly held shares, Baranick holds 46,318 vested and unvested options and restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged trading plan, indicating a neutral sentiment.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on insider information.

Comparison to Industry Standards

• Executive stock sales are a normal part of executive compensation, and the use of 10b5-1 plans is a common practice to avoid insider trading concerns.
• Comparable companies such as Guardant Health, Inc. and Natera, Inc. also see regular Form 4 filings from their executives.
• The size of the sale is relatively small compared to the executive's overall holdings.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the small volume of shares sold.

Key Dates